Clinical Trial

Disease: ABCA4 Retinopathy, (NCT06445322)

Disease info:

ABCA4-related retinopathies are a group of inherited eye disorders caused by variants in the ABCA4 gene. ABCA4 encodes a protein found in the retina, specifically in the light-sensitive photoreceptor cells. This protein helps transport potentially harmful substances that form after phototransduction, the process where light is converted into electrical signals for the brain. Health conditions related to variants in ABCA4 include Stargardts disease, cone-rod dystrophy, juvenile age-related macular degeneration and retinitis pigmentosa.

Stargardt disease is a rare genetic eye disorder that primarily leads to progressive central vision loss, while peripheral vision often remains intact. It  is the most common form of juvenile macular degeneration, the signs and symptoms of which begin in childhood. It typically manifests in childhood or early adulthood, though it can develop later in life. The disease affects the macula, a small part of the retina crucial for detailed vision needed for tasks like reading and recognizing faces. Variants in the gene ELOVL4 may also cause disease onset, though ABCA4 is more commonly associated.

Cone-rod dystrophy is a group of eye disorders that lead to progressive vision loss, affecting the retina's light-sensitive cells. There are over 30 types of cone-rod dystrophy, varying by genetic cause and inheritance pattern, and it can occur either alone or as part of a broader syndrome. Mutations in the ABCA4 gene are the leading cause of autosomal recessive cone-rod dystrophy. Additionally, at least 10 different genes have been linked to cone-rod dystrophy inherited through an autosomal dominant pattern.

Stargardt disease primarily affects central vision, leading to symptoms such as blurry vision and difficulty with tasks requiring detailed sight, like reading or recognizing faces. Night blindness, or difficulty adapting to low-light conditions, is also common. Many individuals experience photophobia. While central vision progressively worsens, peripheral vision generally remains unaffected. The severity and speed of progression can vary, but the gradual loss of vision is a hallmark of the disease.

Symptoms of cone-rod dystrophy typically begin in childhood, with reduced visual sharpness and increased sensitivity to light. Over time, individuals experience impaired colour vision, central blind spots, and partial peripheral vision loss. As the disease progresses, night blindness and further peripheral vision decline can limit mobility, and most affected individuals become legally blind by mid-adulthood. Involuntary eye movements (nystagmus) may also develop.

There is currently no cure for ABCA4-related retinopathies. Management focuses on slowing the degenerative process, addressing complications, and providing visual rehabilitation. Additionally, support is offered to help patients cope with the social and psychological challenges associated with vision loss. To slow disease progression, preventive measures include wearing sunglasses to reduce overexposure to visible light and avoiding vitamin A supplements. Regular eye exams are also recommended. 

Frequency:
Stargardt disease and cone-rod dystrophy are estimated to affect approximately 1 in 6,500 and 1 in 30,000 to 40,000 individuals, respectively.
Official title:
Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
Who:

Study contact: 

Name: Associate Director, Clinical Operations

Phone Number: 207-573-0412

Email: researchtrials@ascidian-tx.com

Study Director: Alia Rashid, Ascidian Therapeutics

Partners:
Locations:

United States, California San Francisco, California, United States, 94158 Recruiting University of San Francisco

United States, Florida Gainesville, Florida, United States, 32607 Recruiting Vitreo Retinal Associates

United States, Maryland Baltimore, Maryland, United States, 21218 Recruiting Wilmer Eye Institute at John Hopkins

United States, Massachusetts Boston, Massachusetts, United States, 02114 Recruiting Massachusetts Eye and Ear

United States, Michigan Ann Arbor, Michigan, United States, 48105 Recruiting University of Michigan Kellogg Eye Center

United States, Ohio Cincinnati, Ohio, United States, 45245 Recruiting Cincinnati Eye Institute

United States, Texas Dallas, Texas, United States, 75382 Recruiting Retina Foundation of Texas

United States, Texas Houston, Texas, United States, 77401 Recruiting Retina Consultants of Texas

Study start:
Jun. 20, 2024
Enrollment:
50
Gene editing method:
NA
Type of edit:
NA
Gene:
ABCA4
Delivery method:
NA
Note:
Observational trial
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

The prescreening process will be used to help determine the initial eligibility and interest of potential participants in ACDN-01 clinical trials by conducting assessments of key eligibility criteria before the clinical trial screening procedures are performed.

Last updated: Jun. 23, 2025
close
Search CRISPR Medicine